This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    NCT01372475
Previous Study | Return to List | Next Study

Hymovis™ Versus Placebo in Knee Osteoarthritis (Hymovis)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Fidia Farmaceutici s.p.a.
ClinicalTrials.gov Identifier:
NCT01372475
First received: June 10, 2011
Last updated: March 11, 2014
Last verified: March 2014
  Purpose
Purpose: The purpose of this study is to demonstrate if the intra-articular injection of a new viscoelastic Hydrogel (Hymovis) is superior to Placebo (phosphate buffered saline [PBS] in subjects with symptomatic osteoarthritis of the knee.

Condition Intervention Phase
Knee Osteoarthritis Device: Hymovis Intra-articular Injection Procedure: Phosphate Buffered Saline Injection Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-Centre, Double-Blind, Randomized, Placebo Controlled Study To Evaluate The Safety And Effectiveness Of A New Viscoelastic Hydrogel (Hymovis) In The Treatment Of Knee OA With An Open-Label Extension

Resource links provided by NLM:


Further study details as provided by Fidia Farmaceutici s.p.a.:

Primary Outcome Measures:
  • Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Pain sub-score [ Time Frame: 26 weeks ]
    WOMAC A Pain sub-score


Secondary Outcome Measures:
  • Responder Analysis [ Time Frame: 26 weeks ]
    Outcome Measures in Rheumatoid Arthritis Clinical Trials - Osteoarthritis Research Society International (OMERACT-OARSI) Criteria

  • WOMAC Function [ Time Frame: 26 Weeks ]
    WOMAC C Function sub-score

  • Visual Analog Scale (VAS) WOMAC Pain [ Time Frame: 26 Weeks ]
    Question A1 of WOMAC Pain sub-score

  • WOMAC Global Score [ Time Frame: 26 Weeks ]
  • WOMAC Stiffness sub-score [ Time Frame: 26 Weeks ]
    WOMAC C stiffness sub-score

  • Rescue Medication Usage Pill Count, Failure Outcome [ Time Frame: 26 Weeks ]
  • Patient Global Analysis [ Time Frame: 26 Weeks ]
  • Clinician Responder Analysis [ Time Frame: 26 Weeks ]
  • SF Health Outcome [ Time Frame: 26 Weeks ]

Enrollment: 800
Study Start Date: March 2011
Study Completion Date: February 2013
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Hymovis Viscoelastic Hydrogel
Intra-articular Injection
Device: Hymovis Intra-articular Injection
Hymovis Intra-articular injection
Other Names:
  • HYADD4™
  • Hyaluronic Acid
  • HA
  • Hyaluronate
Placebo Comparator: Placebo
Phosphate Buffered Saline Intra-articular Injection
Procedure: Phosphate Buffered Saline Injection
Placebo Intra-articular injection
Other Names:
  • PBS
  • Saline

  Eligibility

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female ambulant outpatients ≥ 40 years of age with an active lifestyle:
  2. Has a medical history of OA symptoms confirmed at least 3 months prior to the screening visit with radiographic evidence of OA, Kellgren-Lawrence grade 2-3
  3. Discontinuation of any analgesic/NSAID therapy prior to baseline with no intent to resume during study

Exclusion Criteria:

  1. Clinically significant apparent large effusion of the target knee;
  2. Clinically significant valgus/varus deformities, ligamentous laxity or meniscal instability as assessed by the Investigator;
  3. Any musculoskeletal condition affecting the target knee that would impair assessment of the effectiveness in the target knee such as Paget's disease
  4. Medical history of anaphylactic reactions
  5. History of septic arthritis in any joint
  6. Females who are pregnant or breast-feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01372475

  Show 33 Study Locations
Sponsors and Collaborators
Fidia Farmaceutici s.p.a.
Investigators
Study Director: Cynthia Secchieri, PhD Fidia Farmceutici S.p.A.
  More Information

Responsible Party: Fidia Farmaceutici s.p.a.
ClinicalTrials.gov Identifier: NCT01372475     History of Changes
Other Study ID Numbers: R29-09-02
Study First Received: June 10, 2011
Last Updated: March 11, 2014

Keywords provided by Fidia Farmaceutici s.p.a.:
Osteoarthritis
Knee
Hyaluronan
Hyaluronic Acid
Viscoelastic
Hydrogel

Additional relevant MeSH terms:
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Viscosupplements
Protective Agents

ClinicalTrials.gov processed this record on June 26, 2017